©2018 by SYNG Pharmaceuticals I Privacy Policy

Endometriosis

What do patients say?

What do physicians say?

 

Our Innovative Technology

The recent marketing launch of Elagolix®, oral hormone therapy for endometriosis, has re-invigorated the conversation and drawn the attention of global community towards an unmet need for a simple diagnostic and non-hormonal treatment for endometriosis. Elagolix® has a forecast of over $1.15B in sales by 2022. 

 

SYNG believes that our simple blood-test based diagnostic and non-hormone therapy will benefit from this positive market environment and defined regulatory pathway and, as SP012 may have disease-modifying capabilities in comparison to hormonal options, gaining the potential to achieve significant commercial success.

 

 

FOR PARTNERSHIP AND INVESTMENT OPPORTUNITIES

 

 

Market Play

The recent marketing launch of Elagolix®, an oral hormone therapy for endometriosis, has re-invigorated the conversation and drawn the attention of global community towards an unmet need of a simple diagnostic and non-hormonal therapy for endometriosis. Elagolix® has a forecast of over $1.15B in sales by 2022. 

 

SYNG believes that our simple blood-test based diagnostic and non-hormone therapy will benefit from this positive market environment and defined regulatory pathway and, as SP012 may have disease-modifying capabilities in comparison to hormonal options, gaining the potential to achieve significant commercial success.

 

FOR PARTNERSHIP AND INVESTMENT OPPORTUNITIES